Standout Papers

Denosumab in Postmenopausal Women with Low Bone Mineral Density 2006 2026 2012 2019 859
  1. Denosumab in Postmenopausal Women with Low Bone Mineral Density (2006)
    Michael R. McClung, E. Michael Lewiecki et al. New England Journal of Medicine
  2. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study (2023)
    Samuel Lederman, Antonio Cano et al. The Lancet

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 72 standout
Sub-graph 1 of 18

Citing Papers

An empowerment model for managing menopause
2024 Standout
Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT
2023 Standout

Works of Samuel Lederman being referenced

Phase 3 Study of Fezolinetant for Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause [A132]
2022
A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause
2020
and 2 more

Author Peers

Author Last Decade Papers Cites
Samuel Lederman 268 280 186 664 543 17 1.3k
Giuseppe Girasole 156 350 239 638 792 21 1.7k
Vikram Vinod Shanbhogue 189 129 78 296 385 22 1.1k
Firhaad Ismail 90 99 100 505 339 22 1.1k
Alfred H. Moffett 56 138 75 997 768 12 1.4k
Sverre Harvei 130 125 427 396 200 26 1.4k
Luis Augusto Tavares Russo 95 82 166 690 576 22 1.4k
Annette Schlemmer 194 152 238 328 257 21 1.5k
Chun-Ya Han 60 183 56 346 737 20 1.1k
Ogo Egbuna 40 120 106 362 283 36 1.2k
Michael Eschenberg 484 277 375 728 356 16 1.7k

All Works

Loading papers...

Rankless by CCL
2026